Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton (Q74472410)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9556142%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

title

Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9556142%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

author name string

R C Pelger

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9556142%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

N A Hamdy

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9556142%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

A H Zwinderman

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9556142%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

A A Lycklama à Nijeholt

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9556142%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

S E Papapoulos

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9556142%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

publication date

1 April 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9556142%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9556142%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

volume

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9556142%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9556142%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

page(s)

403-408

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9556142%20AND%20SRC:MED&resulttype=core&format=json

Treatment of painful prostatic bone metastases with oral etidronate disodium

11 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2897%2900289-5

7 January 2021

Histomorphometric analysis of sclerotic bone metastases from prostatic carcinoma special reference to osteomalacia

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2897%2900289-5

7 January 2021

Pain relief and quality-of-life assessment following intravenous and oral clodronate in hormone-escaped metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2897%2900289-5

7 January 2021

Effect of oral clodronate on bone pain. A controlled study in patients with metastic prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2897%2900289-5

7 January 2021

Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2897%2900289-5

7 January 2021

Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2897%2900289-5

7 January 2021

Pyridinium cross-links as urinary markers of bone metastases in patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2897%2900289-5

7 January 2021

Spread of prostatic cancer to bone

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2897%2900289-5

7 January 2021

Evaluation of the effect of oral clodronate on skeletal metastases with type 1 collagen metabolites. A controlled trial of the Finnish Prostate Cancer Group

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2897%2900289-5

7 January 2021

Correlation between bone metabolic markers and bone scan in prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2897%2900289-5

7 January 2021

Pamidronate to reduce bone pain in normocalcaemic patient with disseminated prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2897%2900289-5

7 January 2021

Paget's disease of bone: clinical, pathogenetic and therapeutic aspects

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2897%2900289-5

7 January 2021

Application of an in vitro model and a clinical protocol in the assessment of the potency of a new bisphosphonate

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2897%2900289-5

7 January 2021

Modulation of tumour-induced bone resorption by bisphosphonates

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2897%2900289-5

7 January 2021

Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2897%2900289-5

7 January 2021

Short-term metabolic effects of pamidronate in patients with prostatic carcinoma and bone metastases

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2897%2900289-5

7 January 2021

Carcinoma of the prostate: remission of paraparesis with inhibitors of bone resorption

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2897%2900289-5

7 January 2021

A specific method for the analysis of hydroxyproline in tissues and urine

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2897%2900289-5

7 January 2021

Bone metastases: pathogenesis, treatment, and rationale for use of resorption inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2897%2900289-5

7 January 2021

Improved treatment of Paget's disease with dimethylaminohydroxypropylidene bisphosphonate

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2897%2900289-5

7 January 2021

Palliation of painful bone metastases from prostate cancer using sodium etidronate: results of a randomized, prospective, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2897%2900289-5

7 January 2021

The effect of clodronate on bone in metastatic prostate cancer. Histomorphometric report of a double-blind randomised placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2897%2900289-5

7 January 2021

Hormonal therapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2897%2900289-5

7 January 2021

Generalised increase in bone resorption in carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2897%2900289-5

7 January 2021

Palliative pamidronate treatment in patients with bone metastases from breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2897%2900289-5

7 January 2021

The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2897%2900289-5

7 January 2021

Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2897%2900289-5

7 January 2021

10.1016/S8756-3282(97)00289-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9556142%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

1 reference